Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-08-27
2010-06-08
Jiang, Dong (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C530S350000, C530S387100, C530S388100
Reexamination Certificate
active
07732147
ABSTRACT:
There is disclosed a method for diagnosing neurotransmission or developmental disorders in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of the muscle specific tyrosine kinase (MuSK). One such method comprises a) contacting said bodily fluid with said MuSK or an antigenic determinant thereof; and b) detecting any antibody-antigen complexes formed between said receptor tyrosine kinase or an antigenic fragment thereof and antibodies present in said bodily fluid, wherein the presence of said complexes is indicative of said mammal suffering from said neurotransmission or developmental disorders. Also disclosed are kits for use in the diagnosis of neurotransmission and subsequent developmental disorders.
REFERENCES:
patent: 5814478 (1998-09-01), Bowen et al.
patent: 7267820 (2007-09-01), Vincent et al.
patent: WO 99/10494 (1999-03-01), None
Lueck, et al, 2007, Muscle Chloride Channel Dysfunction in Two Mouse Models of Myotonic Dystrophy. J. Gen. Physiol., 129(1): 79-94.
Meinen, et al, 2007. Linker molecules between laminins and dystroglycan ameliorate laminin-α2—deficient muscular dystrophy at all disease stages. J. Cell Biol. 176(7): 979-993.
Lamke, A.K. & Bushby, K.M.D., 2005, Collagen VI related muscle disorders, J. Med. Genet, 42: 673-685.
Behin, et al, 2008, Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscular Disorders 18: 443-446.
Blaes, F., et al., “IgG'from ‘seronegative’ myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor,”Ann Neurol, 47(4): 504-510 (Apr. 2000).
Brooks, E.B., et al., “A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in ‘antibody-negative’ myasthenia gravis,”J. Neuroimmunol., 28(1): 83-93 (Jun. 1990).
Drachman, D.B., “Myasthenia gravis,”N Engl J Med, 330(25): 1797-1810 (Jun. 1994).
Glass, D.J., et al., “Agrin acts via a MuSK receptor complex,”Cell, 85(4): 513-523 (May 1996).
Hoch, W., et al., “Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies,”Nat Med, 7(3): 365-368 (Mar. 2001).
Hoch, W., et al., “Structural domains of agrin required for clustering of nicotine acetylcholine receptors,”EMBO J, 13(12): 2814-2821 (Jun. 1994).
Hopf, C., et al., “Heparin inhibits acetylcholine receptor-aggregation of two distinct steps in the agrin-induced pathway,”Eur J Neurosci, 9(6):1170-1177 (Jun. 1997).
Hopf, C., et al., “Dimerization of the muscle-specific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes,”J Biol Chem, 273(11): 6467-6473 (Mar. 1998).
Hopf, C., et al., “Tyrosine phosphorylation of the muscle-specific kinase is exclusively induced by acetylcholine receptor-aggregating agrin fragments,”Eur J Biochem, 253(2): 382-389 (Apr. 1998).
Lindstrom, J., et al., “Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic values,”Neurology, 26(11): 1054-1059 (Nov. 1976).
Mier, A.K., et al., “Diaphragmatic myasthenia in mother and child,”Postgraduate Med J, 611: 725-727 (1985).
Mossman, S., et al., “Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity,”Lancet, 1(8473): 116-119 (Jan. 1986).
Riemersma, S., et al., “Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function,”J Clin Invest, 98(10): 2358-2363 (Nov. 1996).
Robertson, S.C., et al., “RTK mutations and human syndromes: when good receptors turn bad,”Trends Genet, 16(6): 265-271 (Jun. 2000).
Sanes, J.R., et al., “Development of the vertebrate neuromuscular junction,”Annual Review of Neuroscience, 22: 389-442 (1999).
Saunders, D.B., et al., “Seronegative myasthenia gravis,”Neurology, 48: S40-S45 (1997).
Taylor, S.I., et al., “Syndromes of autoimmunity and hypoglycemia. Autoantibodies directed against insulin and its receptor,”Endocrinol Metab Clin North Am, 18(1): 123-143 (Mar. 1989).
Valenzuela, D.M., et al., “Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury,”Neuron, 15(3): 573-584 (Sep. 1995).
Vincent, A., et al., “Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen,”Lancet: 346(8966): 24-25 (Jul. 1995).
Vincent, A., et al., “Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays,”J Neurol Neurosurg Psychiatry, 48(12): 1246-1252 (Dec. 1985).
Plested, C.P., et al., “AChR phosphorylation and indirect inhibition of AChR function in seronegative MG,”Neurology, 59: 1682-1688 (2002).
Yamamoto, T., et al., “Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM,”Ann Neurol, 30(4): 550-557 (Oct. 1991).
Zhou, H., et al., “Distinct domains of MuSK mediate its ability to induce and to associate with postsynaptic specializations,”J Cell Biol, 146(5): 1133-1146 (Sep. 1999).
Liyanage, Y., et al., “The agrin/muscle specific kinase pathway; new targets for autoimmune and genetic disorders at the neuromuscular junction,”Invited Review, Muscle Nerve, 25(1): 4-16 (Jan. 2002).
Palace, J., et al., “Myasthenia gravis: diagnostic and management dilemmas,”Curr Opin Neurol, 14(5): 583-589 (Oct. 2001).
Sanders, D.B., et al., “Clinical aspects of MuSK antibody positive seronegative MB,”Neurology, 60(12): 1978-1980 (2003).
Vincent, A., “Unraveling the pathogenesis of myasthenia gravis,”Nat Rev Immunol, 2(10): 797-804 (Oct. 2002).
Vincent, A., et al., “Seronegative generalized myasthenia gravis: clinical features, antibodies and their targets,”Lancet Neurology, 2: 99-106 (2003).
Sisman, et al.,Indian Pediatrics, 41: 938-940 (2004).
Hoch Werner
Vincent Angela
Hamilton Brook Smith & Reynolds P.C.
Isis Innovation Limited
Jiang Dong
Max-Planck Gesellschaft zur Foerderung der Wissenschaften E.V.
Wegert Sandra
LandOfFree
Neurotransmission disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurotransmission disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurotransmission disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186797